Blog
RSS FeedPosted by Michael Wonder on 06 Sep 2022
Italian Medicines Agency approves reimbursed access to Bylvay (odevixibat) for patients with all PFIC types
6 September 2022 - Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the ...
Posted by Michael Wonder on 11 Apr 2022
Orchard Therapeutics announces reimbursement agreement making Libmeldy available for all eligible MLD patients in Italy
11 April 2022 - Orchard Therapeutics today announced it has reached another historic reimbursement agreement with the Italian Medicines Agency, also ...
Posted by Michael Wonder on 26 Oct 2021
The evolution of the Italian National Health Service
22 October 2021 - 40 years ago, Italy saw the birth of a national, universal health care system (Servizio Sanitario Nazionale ...
Posted by Michael Wonder on 26 Oct 2021
Theratechnologies announces reimbursement agreement in Italy for Trogarzo for eligible patients with multi-drug resistant HIV-1
26 October 2021 - Theratechnologies is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, ...
Posted by Michael Wonder on 14 Sep 2021
Drug prices and value of oncology drugs in Italy
13 September 2021 - The main objective of this study was to evaluate the potential role of efficacy data and other ...
Posted by Michael Wonder on 26 Jun 2021
Vertex announces new portfolio reimbursement agreement in Italy including Kaftrio, Symkevi and additional indications of Orkambi and Kalydeco for eligible patients with cystic fibrosis
25 June 2021 - Reimbursement agreement also includes certain future indication extensions across all Vertex cystic fibrosis medicines. ...
Posted by Michael Wonder on 21 Jan 2021
Italy ponders suing Pfizer for delays in coronavirus vaccine
21 January 2021 - Italy's coronavirus commissioner is pressing ahead with plans to take legal action against Pfizer after the ...
Posted by Michael Wonder on 14 Sep 2020
Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions
10 September 2020 - The purpose of this study was to evaluate the current state of health economic evaluations submitted by ...
Posted by Michael Wonder on 06 Aug 2020
Italy becomes first country to require pharma to disclose public funding for R&D costs
6 August 2020 - Amid growing clamour for more transparency from the pharmaceutical industry, Italy has become the first country ...
Posted by Michael Wonder on 10 Jun 2020
Akcea announces approval for reimbursement of Tegsedi (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
8 June 2020 - Tegsedi is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Italy for at-home ...
Posted by Michael Wonder on 26 Nov 2019
Using GRADE methodology to assess innovation of new medicinal products in Italy
25 November 2019 - In April 2017 the Italian Medicine Agency developed new criteria to grant any new medicinal product with ...
Posted by Michael Wonder on 13 Nov 2019
Clovis Oncology announces reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Italy
13 November 2019 - Rucaparib now reimbursed in several countries in Europe with additional countries to follow in 2020. ...
Posted by Michael Wonder on 12 Mar 2019
Why the Italian health minister is pushing for global transparency on drug pricing
12 March 2019 - Last month, the Italian government asked the World Health Assembly to adopt a resolution to require drug ...
Posted by Michael Wonder on 18 Apr 2018
Italy serves cautionary lesson for new Trump drug plan
17 April 2018 - The Trump administration is pushing drug plans that tie costs to performance as a way to lower ...
Posted by Michael Wonder on 24 Feb 2018
Italy continues protest against EMA move to Amsterdam
23 February 2018 - The Italian protest against the relocation of the EMA from London to Amsterdam continued during a ...